LIPOCINE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.98 USD | +16.02% |
|
-5.37% | +221.86% |
| 06-10 | Lipocine Inc. Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late-Breaking Session at EASL Congress 2024 | CI |
| 05-09 | Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M | MT |
Chart calendar Lipocine Inc.
c8.QR5WAN3jdiax5fCpXtq0_gIgc3ScJvxCIMbhN-hSaCo.LEkXdbylGEDzppH6N5vYqU9nBzXeSogRUqWVU4I9AEt2KCJXs406VMCItQ~01b2fe56ab700446eadfecc94fc52bf8
Upcoming events on Lipocine Inc.
Past events on Lipocine Inc.
| 08/06/2024 14:15 | European Association for the Study of the Liver Congress - Abstract No. LP139 |
| 05/06/2024 17:00 | Annual General Meeting |
| 09/05/2024 13:00 | Q1 2024 Earnings Release |
| 11/04/2024 13:30 | LPCN 2401 Phase 2 Clinical Study Results Call |
| 18/03/2024 17:00 | Roth Conference |
| 07/03/2024 13:00 | Q4 2023 Earnings Release |
| 08/01/2024 | LifeSci Partners Corporate Access Event |
| 08/01/2024 23:00 | Biotech Showcase |
| 13/11/2023 19:45 | American Association for the Study of Liver Diseases Conference - Abstract Number 5003 |
| 08/11/2023 13:00 | Q3 2023 Earnings Release |
| 24/10/2023 20:00 | H.C. Wainwright NASH Investor Conference |
| 27/09/2023 20:00 | Cantor Fitzgerald Global Healthcare Conference |
| 10/08/2023 13:00 | Q2 2023 Earnings Release |
| 27/07/2023 13:30 | LPCN 1148 Phase 2 Clinical Study Results Call |
| 26/06/2023 12:00 | H.C. Wainwright Neuropsychiatry Virtual Conference |
| 24/06/2023 14:30 | European Association for the Study of the Liver Congress |
| 23/06/2023 08:00 | European Association for the Study of the Liver Congress - Poster No: FRI-466 |
| 21/06/2023 08:00 | European Association for the Study of the Liver Congress - Poster No: WED-358 |
| 16/05/2023 13:30 | LPCN 1154 Phase I LiFT Study Results Call |
| 11/05/2023 11:00 | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,16 0,20 -17.51% | 0,00 0,00 - | 16,1 3,75 330.23% | 0,50 1,41 -64.51% | -2,85 -3,07 7.05% | 8,95 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -12,9 -12,5 -3.2% | -18,0 -17,1 -5.07% | 3,15 -10,5 130.09% | -12,1 -12,4 2.5% | -17,9 -19,3 7.14% | -9,29 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,0 -12,8 -1.62% | -21,0 -20,4 -2.55% | -0,63 -13,0 95.11% | -10,8 -11,3 5.14% | -16,4 -18,0 9.11% | -8,85 |
|
Net income Million USD | Released Forecast Spread | -13,0 -12,8 -1.62% | -21,0 -20,4 -2.55% | -0,63 -13,0 95.11% | -10,8 -11,3 5.13% | -16,4 -18,0 9.11% | -8,40 |
|
EPS USD | Released Forecast Spread | -8,50 -8,50 0% | -6,46 -6,29 -2.7% | -0,17 -2,49 93.18% | -2,04 -2,21 7.69% | -3,10 -2,99 -3.68% | -1,00 |
| Announcement Date | 13/03/20 | 11/03/21 | 09/03/22 | 10/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 2,00 - | 0,50 0,26 94.55% | 0,00 0,70 - | 0,00 0,91 - | 0,05 0,78 -92.92% | 0,00 0,26 - | -3,12 0,31 -1116.94% | 0,22 0,00 - | 7,62 0,00 - | 0,29 | 0,39 | 0,65 | 1,50 | 3,25 |
|
EBIT Million USD | Released Forecast Spread | -3,13 -1,52 -105.69% | -3,53 -3,37 -4.8% | -2,90 -3,07 5.5% | -2,56 -2,90 11.73% | -4,34 -2,47 -75.62% | -3,96 -3,31 -19.48% | -7,04 -3,20 -120.24% | -2,59 -3,97 34.69% | 3,22 -3,73 186.51% | -4,21 | -4,22 | -4,08 | -2,73 | -1,03 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -3,49 -1,50 -132.89% | -2,63 -3,38 22.2% | -2,41 -3,05 21.05% | -2,23 -2,83 21.11% | -3,87 -2,45 -58.25% | -3,55 -3,33 -6.65% | -6,65 -3,22 -106.36% | -2,28 -3,92 41.81% | 3,51 -3,68 195.61% | -4,16 | -4,17 | -4,03 | -2,68 | -0,98 |
|
Net income Million USD | Released Forecast Spread | -3,49 -1,50 -132.91% | -2,63 -3,38 22.2% | -2,41 -3,05 21.05% | -2,23 -2,83 21.09% | -3,87 -2,45 -58.26% | -3,55 -3,33 -6.65% | -6,65 -3,22 -106.36% | -2,28 -3,92 41.79% | 3,51 -3,68 195.61% | -4,16 | -4,17 | -4,03 | -2,68 | -0,98 |
|
EPS USD | Released Forecast Spread | -0,68 -0,34 -100% | -0,51 -0,68 25% | -0,51 -0,57 10% | -0,34 -0,51 33.33% | -0,68 -0,43 -60% | -0,68 -0,64 -6.25% | -1,26 -0,60 -110% | -0,42 -0,47 10.64% | 0,66 -0,68 197.06% | -0,78 | -0,37 | -0,35 | -0,23 | -0,08 |
| Announcement Date | 09/05/22 | 08/08/22 | 09/11/22 | 10/03/23 | 11/05/23 | 10/08/23 | 08/11/23 | 07/03/24 | 09/05/24 | - | - | - | - | - |
More events
Past sector events for Lipocine Inc.
| 05/06/2024 08:51 | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
| 17/05/2024 12:00 | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 16/05/2024 12:46 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 06:00 | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 15/05/2024 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 15/05/2024 13:05 | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 15/05/2024 12:00 | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 14/05/2024 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 14/05/2024 21:05 | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 14/05/2024 21:00 | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LPCN Stock
- Calendar Lipocine Inc.
